IO Biotech, Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on developing novel, immune-modulating cancer therapies based on our T-win technology platform to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech serves customers in Denmark.